CAI
Market read
No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 29 directly disclosed connections are confirming.
Invalidation: The isolated read changes if CAI's group or a disclosed connection begins moving with it.
Research brief
No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 29 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No credible peer-relative valuation comparison is available yet.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Because of these limitations, you should consider free cash flow alongside other financial performance measures, including net cash provided by (used in) operating activities, capital expenditures, and our other GAAP results.”10-Q · Aug 5, 2026 ↗
“The blood laboratory increase was primarily driven by an increase in materials and related testing costs of $16.8 million, an increase in labor costs of $1.9 million, and a $1.6 million increase in utilities, rent, and allocated overhead, offset by a decrease…”10-Q · Aug 5, 2026 ↗
“The blood laboratory increase was primarily driven by an increase in materials and related testing costs of $16.8 million, an increase in labor costs of $1.9 million, and a $1.6 million increase in utilities, rent, and allocated overhead, offset by a decrease…”10-Q · Aug 5, 2026 ↗
“This decrease was primarily due to our debt refinancing, resulting in lower debt interest expense of $4.1 million, and the absence of convertible debt instruments in 2026, resulting in lower interest expense of $5.8 million.”10-Q · Aug 5, 2026 ↗
Valuation discipline
Price/sales 5.0× · EV/sales 4.4×. Comparisons use only industry-matched filing peers.
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for CAI. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for CAI. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Other companies offering testing in the precision oncology industry include Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, Quest Diagnostics, and BostonGene.”
“Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability o…”
Depended on by
“In the oncology market, our main competitors for our therapy selection and response monitoring tests include Caris Life Sciences, Inc., Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Guardant Health, Inc., NeoGenomics Laboratories, Inc…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 30 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
CAI is currently a Leader in the organic co-movement group Growth-Oriented Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CAI; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.